In recent years, CD6 has emerged as a potential target for therapy in several autoimmune indications such as multiple sclerosis, Sjögren's syndrome and asthma [69–71], and the humanized anti-CD6 monoclonal antibody Itolizumab is already in clinical use to treat chronic plaque psoriasis, rheumatoid arthritis and COVID-19 [72–74]. Here, CD6 is linked to Sjogren syndrome.